Does US approval for key cancer drug make Cipla shares an attractive buy amid tariff concerns?
Does the approval to sell the much-awaited product in the US make Cipla a compelling buy, especially when Trump’s tariffs are looming on the horizon? “One product approval by itself doesn’t suddenly make a company more attractive,” said Prashant Nair, lead analyst for pharma and healthcare at Ambit Capital. “Earlier-than-expected approval for Abraxane is positive,…
